Kezar Life Sciences KZR
$ 6.46
-0.92%
Quarterly report 2024-Q3
added 11-12-2024
Kezar Life Sciences Balance Sheet 2011-2024 | KZR
Annual Balance Sheet Kezar Life Sciences
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-22.4 M | -28.1 M | -52.1 M | -15.8 M | -8.59 M | -24.2 M | -51 M | -9.75 M | - | - | - | - | - |
Long Term Debt |
10.1 M | 9.83 M | 9.62 M | 4.42 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
3.01 M | 2.56 M | 1.2 M | 1.04 M | 900 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 5.46 M | 2.55 M | 78.4 M | 28.2 M | - | - | - | - | - |
Total Current Liabilities |
17.7 M | 11 M | 8.21 M | 6.44 M | 6 M | 3.34 M | - | - | - | - | - | - | - |
Total Liabilities |
33.7 M | 29.7 M | 21.1 M | 10.9 M | 11.5 M | 5.88 M | 79.9 M | 28.9 M | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-351 M | -249 M | -181 M | -126 M | -84.3 M | -49.2 M | -26 M | -17.5 M | - | - | - | - | - |
Total Assets |
221 M | 300 M | 218 M | 152 M | 89.5 M | 115 M | 54.2 M | 11.4 M | - | - | - | - | - |
Cash and Cash Equivalents |
35.5 M | 40.5 M | 62.9 M | 21.2 M | 15 M | 24.2 M | 51 M | 9.76 M | - | - | - | - | - |
Book Value |
188 M | 270 M | 197 M | 141 M | 78 M | 109 M | -25.7 M | -17.4 M | - | - | - | - | - |
Total Shareholders Equity |
188 M | 270 M | 197 M | 141 M | 78 M | 109 M | -25.7 M | -17.4 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Kezar Life Sciences
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
6.35 M | 7.59 M | 8.83 M | 10.1 M | 10 M | 9.95 M | 9.89 M | 9.83 M | 9.78 M | 9.73 M | 9.68 M | 9.62 M | 3.54 M | 3.84 M | 4.14 M | 4.42 M | 4.42 M | 4.42 M | 4.42 M | 5.46 M | 5.46 M | 5.46 M | 5.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
30 M | 29.2 M | 30 M | 33.7 M | 33.3 M | 31.1 M | 31.7 M | 29.7 M | 21.6 M | 20.1 M | 19.6 M | 21.1 M | 11.4 M | 9.79 M | 11.7 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 5.88 M | 5.88 M | 5.88 M | 5.88 M | 1.98 M | 1.98 M | 1.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-414 M | -394 M | -372 M | -351 M | -319 M | -295 M | -271 M | -249 M | -231 M | -213 M | -197 M | -181 M | -166 M | -152 M | -139 M | -126 M | -126 M | -126 M | -126 M | -84.3 M | -84.3 M | -84.3 M | -84.3 M | -49.2 M | -49.2 M | -49.2 M | -49.2 M | -26 M | -26 M | -26 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
164 M | 180 M | 199 M | 221 M | 249 M | 263 M | 284 M | 300 M | 305 M | 318 M | 252 M | 218 M | 131 M | 140 M | 152 M | 152 M | 152 M | 152 M | 152 M | 89.5 M | 89.5 M | 89.5 M | 89.5 M | 115 M | 115 M | 115 M | 115 M | 54.2 M | 54.2 M | 54.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
34.9 M | 28.3 M | 33 M | 35.5 M | 26.5 M | 28.1 M | 36.1 M | 40.5 M | 64.5 M | 105 M | 38.9 M | 62.9 M | 57.1 M | 26.4 M | 22.9 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 15 M | 15 M | 15 M | 15 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 51 M | 51 M | 51 M | - | 9.75 M | - | - | - | 19.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
134 M | 151 M | 169 M | 188 M | 216 M | 232 M | 252 M | 270 M | 283 M | 297 M | 232 M | 197 M | 119 M | 130 M | 141 M | 141 M | 141 M | 141 M | 141 M | 78 M | 78 M | 78 M | 78 M | 109 M | 109 M | 109 M | 109 M | 52.2 M | 52.2 M | 52.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
134 M | 151 M | 169 M | 188 M | 216 M | 232 M | 252 M | 270 M | 283 M | 297 M | 232 M | 197 M | 119 M | 130 M | 141 M | 141 M | 141 M | 141 M | 141 M | 78 M | 78 M | 78 M | 78 M | 109 M | 109 M | 109 M | 109 M | -25.7 M | -25.7 M | -25.7 M | - | -17.4 M | - | - | - | -8.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency